L
Lengo Therapeutics
Precision oncology therapeutics targeting oncogenic driver mutations
About Lengo Therapeutics
Lengo Therapeutics, a biopharmaceutical company founded in 2020, specialized in developing precision medicines for oncology. The company focused on creating novel, small-molecule precision therapeutics designed to target driver mutations in cancer. Lengo Therapeutics was founded by Tracy Saxton and was led by CEO Enoch Kariuki. The firm operated out of San Diego, California, and was backed by investors including Frazier Healthcare Partners and Velosity Capital.
The company's primary initiative was the development of inhibitors for protein kinases with EGFR exon 20 insertion mutations, which are linked to poor prognoses in non-small cell lung cancer (NSCLC) and other solid tumors. Its lead compound, LNG-451, is an oral precision therapy developed for the treatment of NSCLC in patients with these specific mutations. Preclinical data indicated that LNG-451 potently inhibits common EGFR exon 20 insertion variants with high selectivity and is highly brain-penetrant, showing significant activity in preclinical models of intracranial disease.
In November 2021, Blueprint Medicines announced its definitive agreement to acquire Lengo Therapeutics, a deal that was finalized in December 2021. The acquisition was valued at $250 million in cash upfront, with an additional $215 million in potential milestone payments based on regulatory and sales achievements. The acquisition was intended to bolster Blueprint Medicines' pipeline in precision oncology, particularly for EGFR-driven lung cancer. Following the acquisition, Lengo Therapeutics submitted an Investigational New Drug (IND) application for LNG-451 to the U.S. Food and Drug Administration (FDA) in December 2021.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2021 | $250M | $250M | Blueprint Medicines | ↗ |
| SERIES A✓Equity / VC | May 2020 | $15M | $60M | Frazier Healthcare Partners | — |
Growth signals
Lengo Therapeutics's team declined 66.7% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lengo Therapeutics in the Chula Vista ecosystem
The Lengo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Frazier Healthcare Partners
Other known investors2 additional known investors
Blueprint Medicines
Spur Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lengo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lengo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.